Meiji Holdings Co Ltd
2269: XTKS (JPN)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|jsh | LOCK|^>W^ | LOCK|S@%nWk# |
Meiji Earnings: Pharmaceutical Upside Offsets Near-Term Food Headwinds; Retain Fair Value
Meiji's March-quarter revenue of JPY 291 billion was up 3.3%, while operating income was up 27.4%, driven by a 150-basis-point margin expansion. Management guides fiscal 2026 (ending March 2027) operating income to grow 5%, with strength in pharmaceuticals offset by flat domestic food earnings.
